Leerink Swann Reiterates “Outperform” Rating for Flamel Technologies SA (FLML)
Flamel Technologies SA (NASDAQ:FLML)‘s stock had its “outperform” rating reaffirmed by investment analysts at Leerink Swann in a research report issued to clients and investors on Tuesday. They currently have a $16.00 price target on the stock. Leerink Swann’s target price indicates a potential upside of 25.10% from the company’s previous close.
Separately, Zacks Investment Research upgraded Flamel Technologies SA from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Flamel Technologies SA currently has a consensus rating of “Buy” and a consensus price target of $18.63.
Shares of Flamel Technologies SA (NASDAQ:FLML) opened at 12.79 on Tuesday. Flamel Technologies SA has a 12-month low of $7.56 and a 12-month high of $19.78. The firm’s 50-day moving average price is $13.73 and its 200 day moving average price is $11.76. The firm has a market cap of $527.47 million, a P/E ratio of 30.97 and a beta of 1.42.
Flamel Technologies SA (NASDAQ:FLML) last announced its earnings results on Monday, August 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.06 by $0.08. Flamel Technologies SA had a net margin of 12.11% and a return on equity of 25.19%. The firm earned $38.90 million during the quarter, compared to analyst estimates of $32.80 million. During the same period in the prior year, the business posted $0.34 EPS. The firm’s quarterly revenue was down 20.0% compared to the same quarter last year. On average, equities analysts expect that Flamel Technologies SA will post ($1.08) earnings per share for the current fiscal year.
In other Flamel Technologies SA news, Director Craig R. Stapleton bought 20,000 shares of Flamel Technologies SA stock in a transaction dated Friday, August 26th. The stock was bought at an average cost of $13.76 per share, for a total transaction of $275,200.00. Following the purchase, the director now owns 509,678 shares of the company’s stock, valued at approximately $7,013,169.28. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Francis Fildes sold 15,000 shares of Flamel Technologies SA stock in a transaction that occurred on Thursday, September 22nd. The stock was sold at an average price of $13.45, for a total value of $201,750.00. Following the transaction, the director now owns 15,000 shares of the company’s stock, valued at $201,750. The disclosure for this sale can be found here. 4.45% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the company. Public Employees Retirement System of Ohio acquired a new position in shares of Flamel Technologies SA during the second quarter valued at approximately $451,000. Stifel Financial Corp increased its position in shares of Flamel Technologies SA by 11.4% in the second quarter. Stifel Financial Corp now owns 49,000 shares of the company’s stock valued at $1,187,000 after buying an additional 5,000 shares in the last quarter. Point72 Asset Management L.P. increased its position in shares of Flamel Technologies SA by 28.7% in the second quarter. Point72 Asset Management L.P. now owns 461,839 shares of the company’s stock valued at $4,960,000 after buying an additional 102,881 shares in the last quarter. Iguana Healthcare Management LLC acquired a new position in shares of Flamel Technologies SA during the second quarter valued at approximately $806,000. Finally, Parametric Portfolio Associates LLC increased its position in shares of Flamel Technologies SA by 1.2% in the second quarter. Parametric Portfolio Associates LLC now owns 351,263 shares of the company’s stock valued at $3,773,000 after buying an additional 4,206 shares in the last quarter. Institutional investors own 70.33% of the company’s stock.
About Flamel Technologies SA
Flamel Technologies SA is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its polymer based technology. The Company has a balanced business model consisting of an Unapproved Marketed Drugs (UMDs) business with over two approved products in the United States, Bloxiverz (neostigmine methylsulfate injection) and Vazculep (phenylephrine hydrochloride injection) that are marketed; a branded pediatric business, and a branded business, focusing on the development of products utilizing Flamel’s drug delivery platforms.
Receive News & Stock Ratings for Flamel Technologies SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flamel Technologies SA and related stocks with our FREE daily email newsletter.